210 related articles for article (PubMed ID: 21430488)
1. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Karayal ON; Glue P; Bachinsky M; Stewart M; Chappell P; Kolluri S; Cavus I
J Psychiatr Pract; 2011 Mar; 17(2):100-9. PubMed ID: 21430488
[TBL] [Abstract][Full Text] [Related]
2. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
4. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
Kinon BJ; Lipkovich I; Edwards SB; Adams DH; Ascher-Svanum H; Siris SG
J Clin Psychopharmacol; 2006 Apr; 26(2):157-62. PubMed ID: 16633144
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
6. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
Kudla D; Lambert M; Domin S; Kasper S; Naber D
Eur Psychiatry; 2007 Apr; 22(3):195-202. PubMed ID: 17140769
[TBL] [Abstract][Full Text] [Related]
9. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia.
Ganesan S; Agambaram V; Randeree F; Eggens I; Huizar K; Meulien D;
Curr Med Res Opin; 2008 Jan; 24(1):21-32. PubMed ID: 18021496
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
Johnsen E; Kroken RA; Wentzel-Larsen T; Jørgensen HA
BMC Psychiatry; 2010 Mar; 10():26. PubMed ID: 20334680
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
13. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.
Simpson GM; O'Gorman CJ; Loebel A; Yang R
CNS Spectr; 2008 Oct; 13(10):898-905. PubMed ID: 18955945
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
DelBello MP; Versavel M; Ice K; Keller D; Miceli J
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Zhang Y; Dai G
Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
[TBL] [Abstract][Full Text] [Related]
20. Switching to ziprasidone in the clinical practice setting: an open-label study.
Gutiérrez Fraile M; de la Gándara Martín JJ; Bobes García J
Int J Psychiatry Med; 2013; 45(2):125-42. PubMed ID: 23977817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
